COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.
作者信息
Spiera Emily, Agrawal Manasi, Ungaro Ryan C
机构信息
The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Gastroenterology. 2022 Mar;162(3):987-988. doi: 10.1053/j.gastro.2021.10.004. Epub 2021 Oct 6.
Abstract
摘要
相似文献
1
COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.
Gastroenterology. 2022 Mar;162(3):987-988. doi: 10.1053/j.gastro.2021.10.004. Epub 2021 Oct 6.
2
Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
Infection. 2022 Jun;50(3):791-793. doi: 10.1007/s15010-021-01729-z. Epub 2021 Dec 2.
3
A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
Kidney Int. 2022 Apr;101(4):825-826. doi: 10.1016/j.kint.2022.01.017. Epub 2022 Feb 12.
4
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine.
Lancet Microbe. 2022 Aug;3(8):e561. doi: 10.1016/S2666-5247(22)00150-1. Epub 2022 May 31.
5
Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Am J Cardiol. 2022 Mar 15;167:155-157. doi: 10.1016/j.amjcard.2021.12.007. Epub 2022 Jan 19.
6
Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
Int J Rheum Dis. 2022 Mar;25(3):353-363. doi: 10.1111/1756-185X.14279. Epub 2022 Jan 3.
7
Safety of mRNA-Based Vaccines for SARS CoV-2.
Chem Res Toxicol. 2021 Aug 16;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. Epub 2021 May 19.
8
Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e743-e744. doi: 10.1111/jdv.18253. Epub 2022 Jun 3.
9
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
10
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
Lancet Infect Dis. 2022 Jun;22(6):747-748. doi: 10.1016/S1473-3099(22)00123-2. Epub 2022 Mar 7.
引用本文的文献
1
COVID-19 Vaccines for Adults and Children with Autoimmune Gut or Liver Disease.
Vaccines (Basel). 2022 Dec 5;10(12):2075. doi: 10.3390/vaccines10122075.
2
Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.
Gastroenterol Hepatol. 2023 Jan;46(1):48-53. doi: 10.1016/j.gastrohep.2022.05.006. Epub 2022 May 20.
3
Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Dig Liver Dis. 2022 Jun;54(6):713-721. doi: 10.1016/j.dld.2022.03.005. Epub 2022 Mar 22.
Zotero 插件